New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
09:06 EDTNUVA, ABCO, BSX, CMN, DGX, ELGX, FLDM, STJ, THORPiper Jaffray's technical analyst holds an analyst/industry conference call
Technical Analyst Johnson provides a technical review of the firm's Medical Technology covered universe ahead of 4Q results on an Analyst/Industry conference call to be held on January 10 at 10 am.
News For ABCO;BSX;CMN;DGX;ELGX;FLDM;STJ;THOR;NUVA From The Last 14 Days
Check below for free stories on ABCO;BSX;CMN;DGX;ELGX;FLDM;STJ;THOR;NUVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
05:15 EDTSTJData shows PA pressure monitoring did not adversely affect kidney function
Subscribe for More Information
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
08:02 EDTSTJSt. Jude Medical announces launch of OPTISTM integrated system
St. Jude Medical announced the company has secured CE Mark and FDA clearance for the new OPTISTM Integrated System. The system is a departure from traditional, mobile cart-based diagnostic tools and advances percutaneous coronary intervention optimization via direct installation into a hospitalís cardiac catheterization laboratory, fully integrating optical coherence tomography and fractional flow reserve into PCI workflow.
07:45 EDTBSX, STJCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:21 EDTSTJ, THORHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 13, 2014
18:16 EDTSTJSt. Jude Medical announces data from the EnligHTN III study
St. Jude Medical announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. The results were presented during the 26th annual Transcatheter Cardiovascular Therapeutics scientific symposium.
September 12, 2014
15:03 EDTBSX, STJSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
10:00 EDTABCOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Cedar Realty Trust (CDR) upgraded to Buy from Hold at KeyBanc... E.ON AG (EONGY) upgraded to Overweight from Neutral at JPMorgan... Genuine Parts (GPC) upgraded to Buy from Hold at BB&T... Inland Real Estate (IRC) upgraded at KeyBanc... Littelfuse (LFUS) upgraded to Outperform from Perform at Oppenheimer... Netflix (NFLX) upgraded to Equal Weight from Underweight at Barclays... Noranda Aluminum (NOR) upgraded to Buy from Neutral at Goldman... OCI Partners (OCIP) upgraded to Buy from Neutral at Citigroup... Ramco-Gershenson (RPT) upgraded at KeyBanc... Sprint (S) upgraded to Outperform from Market Perform at Cowen... T-Mobile (TMUS) upgraded to Buy from Hold at Argus... The Advisory Board (ABCO) upgraded to Outperform at Wells Fargo.
07:29 EDTABCOThe Advisory Board upgraded to Outperform at Wells Fargo
Subscribe for More Information
06:40 EDTABCOThe Advisory Board upgraded to Outperform from Market Perform at Wells Fargo
September 11, 2014
11:15 EDTABCOThe Advisory Board reaffirms 2014 revenue outlook $570M-$580M
Subscribe for More Information
09:11 EDTABCOThe Advisory Board to host analyst and investor day
Subscribe for More Information
September 9, 2014
16:46 EDTTHORThoratec announces start of Heartmate III U.S. clinical trial
Subscribe for More Information
September 8, 2014
16:06 EDTDGXQuest Diagnostics: More people testing positive for chikungunya virus in U.S.
Subscribe for More Information
07:26 EDTSTJ, BSXMorgan Stanley to hold a conference
Subscribe for More Information
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.
September 4, 2014
10:01 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information
September 3, 2014
10:00 EDTDGXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:17 EDTDGXQuest Diagnostics upgraded to Conviction Buy from Buy at Goldman
Goldman upgraded Quest Diagnostics to Conviction Buy from Buy based on expectations for improving industry volumes, cost cutting focus, margin expansion potential, and capital allocation. Price target raised to $78 from $66.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use